LIDDS Lidds AB

LIDDS Interim report January – June 2021

LIDDS Interim report January – June 2021

JANUARY – JUNE 2021

  • Net sales amounted to MSEK 0.8 (0.0)
  • Operating expenses amounted to MSEK -21.3 (-13.3)
  • Profit/loss before and after tax amounted to MSEK -20.6 (-13.3)
  • Earnings per share amounted to SEK -0.68 (-0.54)
  • Cash flow from operating activities amounted to MSEK -23.5 (-12.1)
  • Equity amounted to MSEK 65.1 (31.7) and the debt/equity ratio was 89% (82%)

APRIL – JUNE 2021

  • Net sales amounted to MSEK 0.1 (0.0)
  • Operating expenses amounted to MSEK -9.9 (-5.3)
  • Profit/loss before and after tax amounted to MSEK -9.8 (-5.3)
  • Earnings per share amounted to SEK -0.32 (-0.21)
  • Cash flow from operating activities amounted to MSEK -11.8 (-6.3)
  • Equity amounted to MSEK 65.1 (31.7) and the debt/equity ratio was 89% (82%)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER 2021

  • The AGM resolved to authorize the board of directors to, on one or more occasions during the period until the next annual general meeting, with or without deviation from the shareholders preferential rights, decide on issue of shares. The AGM also resolved to establish a warrants-based incentive programme 2021/2024 for the CEO and other key-persons.
  • Jenni Björnulfson was recruited as CFO and will start at LIDDS on October 1, 2021.
  • In May, the Swedish Medical Products Agency approved the application for a new clinical study at Uppsala University Hospital. The study will assess intratumoral injections of NZ-DTX Depot, containing the cytotoxic agent docetaxel, in patients with prostate cancer who are scheduled for prostatectomy.
  • In June, LIDDS carried out a directed share issue and was provided with MSEK 45, before issue costs.

SIGNIFICANT EVENTS FOLLOWING THE END OF THE PERIOD

  • As part of the warrants-based incentive programme 2021/2024, a total of 146.000 warrants were subscribed to, by the CEO and key-persons at LIDDS. The remaining warrants is kept by LIDDS and will be offered to future key-persons in relation to employment.

The interim report is available on the company’s website, go to

For more information, please contact: 

Nina Herne, CEO, LIDDS +46 (0)70 714 74 57 

LIDDS AB (PLC) is required to disclose this information in accordance with the EU Market Abuse Regulation. The information was submitted through the agency of the aforementioned contact, for publication on August 26, 2021 at 08:30 CET.

LIDDS AB (PLC) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and is superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens, and also has in-house development projects in the clinical as well as the preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, , +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit .

Attachment



EN
26/08/2021

Underlying

LIDDSLidds AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lidds AB

 PRESS RELEASE
Free
LIDDS LIDDS AB

Report from Extraordinary General Meeting in LIDDS

Report from Extraordinary General Meeting in LIDDS UPPSALA, SWEDEN – LIDDS AB (publ)’s (“LIDDS” or the “Company”) Extraordinary General Meeting was held 11 March 2022 in the Company’s premises in Uppsala. The Extraordinary General Meeting resolved as set out below. Authorisation to issue convertiblesThe Extraordinary General Meeting resolved in accordance with the Board of Directors’ proposal to authorise the Board of Directors to, within the scope of the articles of association, with deviation from the shareholders’ pre-emption rights, on one or several occasions during the period un...

March 11, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

Kommuniké från extra bolagsstämma i LIDDS

Kommuniké från extra bolagsstämma i LIDDS UPPSALA, SVERIGE – LIDDS AB (publ) (”LIDDS” eller ”Bolaget”) höll den 11 mars 2022 extra bolagsstämma i Bolagets lokaler i Uppsala. Den extra bolagsstämman beslutade enligt nedan. Bemyndigande att emittera konvertiblerDen extra bolagsstämman beslutade i enlighet med styrelsens förslag att bemyndiga styrelsen att inom ramen för gällande bolagsordning, med avvikelse från aktieägarnas företrädesrätt, vid ett eller flera tillfällen intill nästkommande årsstämma, fatta beslut om emission av konvertibler i Bolaget. Sådan emission ska endast kun...

March 11, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

LIDDS publishes agenda for the company's Capital Markets Day 2022

LIDDS publishes agenda for the company's Capital Markets Day 2022 UPPSALA, SWEDEN – LIDDS AB (publ) announced today the agenda for the Capital Markets Day to be held on March 9, 2022, for investors, analysts and media. Agenda Capital Markets Day 2022 15.00-15.10 Welcome - Nina Herne, CEO15.10-15.45 Presentation of LIDDS company strategy and drug delivery technology - Nina Herne, CEO15.45-16.45 Update on LIDDS pipeline and clinical programs - Johan Harmenberg, CMO16.45-16.55 Break16.55-17.15  Financial update - Jenni Björnulfson, CFO17.15-18.00 Q&A session - Nina He...

March 4, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

LIDDS publicerar agenda för bolagets kapitalmarknadsdag 2022

LIDDS publicerar agenda för bolagets kapitalmarknadsdag 2022 UPPSALA, Sverige – LIDDS AB (publ) meddelade i dag agendan för den kapitalmarknadsdag som kommer att arrangeras den 9 mars 2022 för investerare, analytiker och media. Agenda Kapitalmarknadsdag 2022 15.00-15.10 Välkomnande - Nina Herne, vd15.10-15.45 Presentation av LIDDS uppdaterade strategi och bolagets drug delivery-teknologi - Nina Herne, vd15.45-16.45 Uppdatering kring LIDDS projektportfölj och kliniska program - Johan Harmenberg, CMO16.45-16.55  Paus16.55-17.15   Finansiell uppdaterin...

March 4, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

Complement to press release: Notice of Extraordinary General Meeting o...

Complement to press release: Notice of Extraordinary General Meeting of LIDDS AB (publ) In the press release published on February 22, 2022, the appendix with the notice was missing. The notice is attached to this press release, which otherwise corresponds with the previously issued press release. The supplement was submitted for publication on February 24, 2022. Notice of Extraordinary General Meeting in LIDDS AB (publ) The shareholders in LIDDS AB (publ) (reg. no. 556580-2856) (the “Company” or “LIDDS”) are hereby convened to the Extraordinary General Meeting on Friday, 11 March 202...

February 24, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch